## Supplementary Material

## 1 Supplementary Table

### 1.1 Supplementary Table 1: Tool and commands for tools

| Tool | Command |
| :---: | :---: |
| Cap3 | cap3 <gene_reads.fa> |
| BLAT | blat - stepSize=10 <br> -repMatch=1024 \} <br> \(-m i n S c o r e=20 <br> ) <br> -minldentity=100 \} <br> -out=blast8 \} <br> <hg19_reference> <contigs.fa> <br> <outputname> |
| Fastp | fastp <R1.fastq.gz> <R2.fastq.gz> |
| STAR- <br> Fusion | STAR-Fusion --left_fq \$\{samplename\}_R1.fastq.gz --right_fq \$\{samplename\}_R2.fastq.gz --output_dir star_output --genome_lib_dir GRCh37_gencode_v19_CTAT_lib_Mar012021.plug-nplay/ctat_genome_lib_build_dir -CPU 1 |
| JAFFA | JAFFA-version-1.09/tools/bin/bpipe run JAFFA-version-1.09/JAFFA_hybrid.groovy <SAMPLEFOLDER>/*.fastq.gz |
| TOPHAT- <br> Fusion | tophat-2.1.0.Linux_x86_64/tophat --bowtie1 -o <tophat_OUTPUT_folder> -p 1 --fusion-search --keep-fasta-order --no-coverage-search -r 0 --mate-std-dev 500 --max-intron-length 100000 --fusion-min-dist 100000 --fusion-anchor-length 13 --fusion-ignore-chromosomes chrM <hg19_reference> <SAMPLE>_R1.fastq.gz <SAMPLE>_R2.fastq.gz |

### 1.2 Supplementary Table 2: Genes targeted in the neurological oncology panel

| NFASC | CLCN6 | BRAF | PCDHGA1 | MET | MKRN1 | CLIP2 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| TFG | ESR1 | FXR1 | NAV1 | YAP1 | EWSR1 | GFI1B |
| PKD1 | NRF1 | EGFR | RECK | MYB | VCL | JPX |
| NTRK3 | AGBL4 | GLI1 | BCAN | AFAP1 | SRGAP3 | ST6GAL1 |
| FAM131B | PDGFRA | MAMLD1 | RELA | NDRG1 | DIP2C | UBE2J2 |
| MYBL1 | ELAVL3 | MMP16 | DDX31 | C11orf95 | CXXC5 | FOXR2 |
| GFI1 | ETV6 | NAB2 | FYCO1 | FGFR3 | RNF130 | SEPT14 |
| BIRC5 | FLI1 | NTRK2 | FAM118B | KIAA1549 | PVT1 |  |
| FGFR1 | GNAI1 | TACC1 | BTBD1 | PRKCA | BEND2 |  |
| STAT6 | MN1 | TACC3 | C8orf34 | PTPRZ1 |  |  |
| PCSK5 | MST1R | ATG7 | SLC44A1 | RAF1 |  |  |
| TPM3 | MYC | QKI | NSD2 | NELFE |  |  |
| LINC01420 | NTRK1 | MACF1 | NACC2 | SLIT1 |  |  |

### 1.3 Supplementary Table 3: Gene Targets in Sarcoma assay

| ACTB | AHRR | ALK | ASPSCR1 | ATF1 | ATIC | SQSTM1 | SRSF3 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| BCOR | BRD3 | BRD4 | CAMTA1 | CARS | CCNB3 | SS18 | STAT6 |
| CDH11 | CNBP | COL1A1 | COL1A2 | COL3A11 | COL6A3 | TCF12 | TFE3 |


| CDXI | CD63 | CEP128 | CIC | CITED2 | CLTC | TPM4 | USP6 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CREB1 | CREB3L1 | CREB3L2 | CSF1 | CXorf67 | C11orf95 | WWTRI | YWHAE |
| DDIT3 | DUX4 | DVL2 | EML4 | EPC1 | EP400 | SRF | SSXI |
| ERG | ETV1 | ETV4 | ETV6 | EWSR1 | FEV | SS18L1 | SUZ12 |
| FGFR1 | FLII | FN1 | FOSB | FOXO1 | FOXO4 | TEAD1 | TFG |
| FUS | GLII | HAS2 | HEY1 | HMGA2 | IRF2BP2 | TPR | $V C L$ |
| JAZF1 | KIRREL | KLF17 | LAMTOR1 | LPP | MAML3 | YAP1 | ZC3H7B |
| MBTD | MEAF6 | MED12 | MIR143HG | MKL2 | MYH9 | ZFP36 | ZNF444 |
| NAB2 | NCOA1 | NCOA2 | NFATC2 | NFIB | NOTCH1 | VGLL2 | WT1 |
| NOTCH2 | NR4A3 | NTRK1 | NTRK3 | NUMA1 | NUTM1 | SSX2 | SSX4 |
| NUTM2B | $O M D$ | OPHN1 | PATZ1 | PAX3 | PAX7 | S100A10 | TAF15 |
| PBXI | PBX3 | PDGFB | PDPN | PHF1 | PLAG1 | THRAP3 | TPM3 |
| PLPP3 | POU5F1 | PPFIBP1 | PRDM10 | PRKCA | PRKCB |  |  |
| PRKCD | RAB2A | RAD51B | RANBP2 | RNF213 | RRAGB |  |  |
| SEC31A | SERPINE1 | SETBP1 | SFMBT1 | SMARCA5 | SP3 |  |  |

1.4 Supplementary Table 4: Common transcript events accounted for reporting by the SeekFusion pipeline

| GeneA | GeneA | Chromosome | Start | End |
| :--- | :--- | :--- | :--- | :--- |

Supplementary Material

| GLII | GLII | chr12 | 57854337 | 57858456 |
| :---: | :---: | :---: | :---: | :---: |
| GLII | GLII | chr12 | 57857574 | 57858485 |
| BIRC5 | BIRC5 | chr17 | 76212862 | 76218908 |
| PDGFRA | PDGFRA | chr4 | 55133908 | 55139704 |
| $E G F R$ | $E G F R$ | chr7 | 55229324 | 55238868 |
| $E G F R$ | $E G F R$ | chr7 | 55228031 | 55240676 |
| $E G F R$ | $E G F R$ | chr7 | 55087058 | 55223523 |
| $E G F R$ | $E G F R$ | chr7 | 55268106 | 55272949 |
| $E G F R$ | $E G F R$ | chr7 | 55268106 | 55270210 |
| $E G F R$ | $E G F R$ | chr7 | 55229249 | 55233060 |
| $E G F R$ | $E G F R$ | chr7 | 55087058 | 55266410 |
| $E G F R$ | $E G F R$ | chr7 | 55211181 | 55218987 |
| EGFR | $E G F R$ | chr7 | 55233130 | 55237999 |
| $E G F R$ | $E G F R$ | chr7 | 55177651 | 55209979 |
| $E G F R$ | $E G F R$ | chr7 | 55087058 | 55209979 |
| $E G F R$ | $E G F R$ | chr7 | 55219055 | 55220239 |
| $E G F R$ | $E G F R$ | chr7 | 55221845 | 55223523 |
| $E G F R$ | $E G F R$ | chr7 | 55238868 | 55233130 |


| EGFR | EGFR | chr7 | 55270210 | 55269475 |
| :--- | :--- | :--- | :--- | :--- |
| EGFR | EGFR | chr7 | 55270318 | 55272949 |
| MST1R | MST1R | chr3 | 49933628 | 49933313 |
| FGFR1 | FGFR1 | chr8 | 38279315 | 38271155 |
| FGFR1 | FGFR1 | chr8 | 38277106 | 38271149 |
| NELFE | NELFE | chr6 | 31922472 | 31922345 |
| PCSK5 | PCSK5 | chr9 | 78547399 | 78682871 |
| RELA | RELA | chr11 | 65430297 | 65429559 |
| BCOR | BCOR | chrX | 39911365 | 39911457 |
| BCOR | BCOR | chrX | 39911374 | 39911466 |
| BCOR | BCOR | chrX | 39911407 | 39911493 |
| BCOR | BCOR | chrX | 39911419 | 39911529 |
| BCOR | BCOR | chrX | 39911365 | 39911457 |
| BCOR | BCOR | chrX | 39911407 | 39911493 |
| BCOR | BCOR | chrX | 39911407 | 39911496 |
| FGFR1 | FGFR1 | chr8 | 38271436 | 38275891 |
|  |  |  |  |  |

### 1.5 Supplementary Table 5: Common artifacts in tools

```
Tool/ Call
pipeli
ne
                                Reason for false positive
```

| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA10 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| :---: | :---: | :---: |
| STARFusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA11 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STARFusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA12 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA3 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA4 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA5 } \\ & \hline \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA6 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA7 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA8 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGA9 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB1 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB2 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB3 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB4 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB6 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STARFusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { PCDHGB7 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |


| STAR- | CTD- | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| :--- | :--- | :--- |
| Fusion | 2328D6.1-- |  |
|  | PCDHGC3 |  |
| STAR- | CTD- | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| Fusion | 2328D6.1-- |  |
|  | PCDHGC4 |  |
| STAR- | CTD- | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| Fusion | 2328D6.1-- |  |
|  | PCDHGC5 |  |
| STAR- | YAP1--HGS | Homology (The HGS end is identical to another region within transcriptome, not a <br> Fusion |
| confident call) |  |  |


| STAR- <br> Fusion | MYB-PCDHGA11 | Homology (PCDHG family homology call) |
| :---: | :---: | :---: |
| STARFusion | MYB-PCDHGA12 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA3 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA4 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA5 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA6 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA7 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA8 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGA9 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB1 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB2 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB3 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB4 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB6 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGB7 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGC3 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGC4 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | MYB-PCDHGC5 | Homology (PCDHG family homology call) |
| STAR- <br> Fusion | FAM131B-BRAFP1 | Pseudogene (BRAFP1 homologous to BRAF) |
| STAR- <br> Fusion | ING5--QKI | Homology (ING5 part maps to multiple regions with high identity) |
| STAR- <br> Fusion | KIAA1549-- <br> CLDN14 | Homology (the part that maps to CLDN14 is identical to a part in KIAA1549) |
| STAR- <br> Fusion | RNU4ATACRAF1 | Homology (the part that maps to RNU4ATAC maps multiply to other parts of transcriptome) |
| STAR- <br> Fusion | EGFR--PARD3 | Low frequency (0.00005\% frequency) |


| STAR- | CTD- | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| :--- | :--- | :--- |
| Fusion | 2328D6.1-- |  |
|  | QKI |  |
| STAR- | ACO79949.1-- | Low complexity (The AC079949.1 region is GC rich ) |
| Fusion | BRAF |  |
| STAR- | MAN1A2-- | Low complexity (MAN1A2 has low complexity with polyA repeats and there is |
| Fusion | QKI | only one C in the reads aligned to MAN1A2) |
| STAR- | MOV10L1-- | Low complexity (MOV10L1 has low complexity with poly T and poly C repeats) |
| Fusion | NTRK2 |  |
| STAR- | QKI--SCD5 | Low complexity (polyA repeats) |
| Fusion |  |  |
| STAR- | RMRP--QKI | Homology (The RMRP part is highly identical to other regions in transcriptome) |
| Fusion |  |  |
| STAR- | PTPRZ1-- | Low frequency (0.00001\%) |
| Fusion | PSMB1 |  |
| STAR- | SMIM4-- | Fusion reads do not span SMIM4 gene for more than 5 bases (PCDHG family <br> Fusion |
| PCDHGA10 | homology) |  |


| STAR- | SMIM4-- | Fusion reads do not span SMIM4 gene for more than 5 bases (PCDHG family <br> fusion |
| :--- | :--- | :--- |
| PCDHGC3 | homology) |  |


| STAR- <br> Fusion | $\begin{aligned} & \text { RP11- } \\ & \text { 317B7.2-- } \\ & \text { STAT6 } \end{aligned}$ | Low complexity (Poly A repeats) |
| :---: | :---: | :---: |
| STAR- <br> Fusion | SRGAP3-AC010642.1 | Homology (The AC010642.1 is homologous to a zinc finger motif that has repeats) |
| STAR- <br> Fusion | SRGAP3-- <br> ZNF8 | Homology (part of read mapped to SRGAP3 also maps to ZNF8 due to homology) |
| STAR- <br> Fusion | BCAN--PGLS | Low complexity (The PGLS part has lot of GC bases) |
| STAR- <br> Fusion | $\begin{aligned} & \text { GS1- } \\ & \text { 165B14.2-- } \\ & \text { QKI } \end{aligned}$ | Low complexity (The GS1-165B14.2 part has lot pf polyA repeats) |
| STAR- <br> Fusion | $\begin{aligned} & \text { KIAA1549-- } \\ & \text { EVX2 } \end{aligned}$ | Low complexity (EVX2 part has lot of T repeats) |
| STAR- <br> Fusion | $\begin{aligned} & \text { QKI-- } \\ & \text { ALO78585.1 } \end{aligned}$ | Homology (The AL078585.1 part is identical to another region in transcriptome) |
| STAR- <br> Fusion | ARSG-PDGFRA | Low complexity (noisy alignments) |
| STAR- <br> Fusion | $\begin{aligned} & \text { EGFR-- } \\ & \text { ZFP36L2 } \end{aligned}$ | Low complexity (The ZFP36L2 gene has lot of GC content) |
| STAR- <br> Fusion | FGFR1--PILRB | Low complexity (repetitive region in PILRB side) |
| STAR- <br> Fusion | PTPRZ1-RN7SL674P | Homology (The RN7SL674P maps to many regions across transcriptome) |
| STAR- <br> Fusion | $\begin{aligned} & \text { PTPRZ1-- } \\ & \text { SNHG16 } \end{aligned}$ | Low complexity (noisy alignments) |
| STAR- <br> Fusion | QKI--LARP4B | Homology (The LARP4B part maps to multiple regions across transcriptome) |
| STAR- <br> Fusion | $\begin{aligned} & \text { RP11- } \\ & \text { 168O16.1-- } \\ & \text { QKI } \end{aligned}$ | Low complexity (RP11-168016.1 has many repeats) |
| STAR- <br> Fusion | SNORD119-- FGFR1 | Low complexity (polyA repeats) |
| STAR- <br> Fusion | $\begin{aligned} & \text { SULT1C2-- } \\ & \text { BRAF } \end{aligned}$ | Low complexity (The SULT1C2 region has poly A repeats) |
| STAR- <br> Fusion | TPM3-MRPS21 | Homology (The regions mapped to TPM3 and MRPS21 map multiple to other regions in transcriptome) |
| STAR- <br> Fusion | ETV6-METTL25 | Homology (The ETV6 first few bases are homologous to other regions in transcriptome) |
| STAR- <br> Fusion | HNRNPK-NTRK2 | Homology (The HNRNPK part multiply maps to other regions in transcriptome) |
| STAR- <br> Fusion | SEZ6--NTRK2 | Homologous regions and low complexity (The SEZ6 part of mapping is homologous to NTRK2 and due to low complexity its mapping) |
| STAR- <br> Fusion | SLC44A1-- <br> ACIN1 | Low complexity (ACIN1 gene has A and G repeats) |
| STAR- <br> Fusion | SLC6A4-- <br> PRKCA | Homology (SLC6A4 part is homologous to PRKCA gene part leading to false call) |


| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2206N4.4-- } \\ & \text { AC016773.1 } \end{aligned}$ | Pseudogene (CTD-2206N4.4 is a classified as a pseudogene) |
| :---: | :---: | :---: |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2206N4.4-- } \\ & \text { TACC3 } \end{aligned}$ | Pseudogene (CTD-2206N4.4 is a classified as a pseudogene) |
| STAR- <br> Fusion | $\begin{aligned} & \text { AC011525.2-- } \\ & \text { QKI } \end{aligned}$ | Homology (AC011525.2 part maps multiply to other regions) |
| STAR- <br> Fusion | RAB2A--QKI | Homology (RAB2A part maps multiple to other regions) |
| STAR- <br> Fusion | $\begin{aligned} & \text { SRGAP3-- } \\ & \text { AC010642.1 } \end{aligned}$ | Homology (Part of AC010642.1 maps identical to SRGAP3 end) |
| STAR- <br> Fusion | QKI--APP | Homology (Part of APP maps to other regions within transcriptome) |
| STAR- <br> Fusion | KIAA1549-EGFR | Low complexity (The KIAA1549 is repetitive) |
| STAR- <br> Fusion | MIR144--QKI | Low complexity (The MIR144 part is repetitive with poly A and poly T repeats) |
| STAR- <br> Fusion | $\begin{aligned} & \text { SRGAP3-- } \\ & \text { RECQL4 } \end{aligned}$ | Low frequency (0.02\%) |
| STAR- <br> Fusion | BCAN--SOX9 | Low complexity (Lot of C repeats on either ends) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & 3148110.1-- \\ & \text { EGFR } \end{aligned}$ | Noisy alignments |
| STAR- <br> Fusion | $\begin{aligned} & \text { EGFR-- } \\ & \text { AC008265.2 } \end{aligned}$ | Pseudogene (AC008265.2 is classified as a pseudogene) |
| STAR- <br> Fusion | EGFR--RTN4 | Low complexity (RTN4 has poly A repeats) |
| STAR- <br> Fusion | FGFR1-MALAT1 | Low complexity (Highly repetitive MALAT1 region causing multiple mappings) |
| STAR- <br> Fusion | HHIP--EGFR | Low complexity (HHIP part of mapping has lot of GA repeats) |
| STAR- <br> Fusion | QKI--CASK | Low complexity (The CASK part has a lot of poly A and T repeats) |
| STAR- <br> Fusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { RAF1 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STAR- <br> Fusion | IGF2--RELA | Noisy alignments |
| STAR- <br> Fusion | $\begin{aligned} & \text { AC009133.14 } \\ & \text {--RELA } \end{aligned}$ | Low complexity (AC009133.14 part is highly repetitive) |
| STAR- <br> Fusion | BCAN--DMD | Low complexity and Homology (DMD part has low complexity and hence aligns multiply across transcriptome) |
| STAR- <br> Fusion | EGFR-PRMT2 | Low complexity (PRMT2 gene has a lot of G repeats) |
| STAR- <br> Fusion | IGF2--FGFR1 | Homology (IGF2 maps multiply to many regions in transcriptome) |


| STAR- <br> Fusion | RP11- <br> 586K2.1-- <br> PRKAR1A | Noisy alignments |
| :---: | :---: | :---: |
| STAR- <br> Fusion | NF1--PRKCA | Low frequency (0.01\%) |
| STARFusion | $\begin{aligned} & \text { CTD- } \\ & \text { 2328D6.1-- } \\ & \text { NTRK2 } \end{aligned}$ | Pseudogene (CTD2328D6.1 is classified as a pseudogene) |
| STARFusion | $\begin{aligned} & \text { RP11- } \\ & 586 K 2.1-- \\ & \text { APOD } \end{aligned}$ | Homology (The RP11-586K2.1 maps identical to other parts of transcriptome) |
| JAFFA <br> Hybri <br> d | NAV1:MTRNR2 | Noisy alignments |
| JAFFA <br> Hybri <br> d | $\begin{aligned} & \text { OLFM2:PCDH } \\ & \text { GA1 } \end{aligned}$ | Low complexity (OLFM2 part has multiple mappings to other parts of transcriptome due to homology) |
| JAFFA <br> Hybri <br> d | SPTBN1:NTR K2 | Low frequency (0.0008\%) |
| JAFFA <br> Hybri <br> d | $\begin{aligned} & \text { RNF144A:PC } \\ & \text { DHGA1 } \end{aligned}$ | Homology (The RNF144A part maps multiple to other regions of transcriptome) |
| JAFFA <br> Hybri <br> d | DHFR:NTRK2 | Noisy alignments with insertion and also homology of DHFR aligned part to other regions |
| JAFFA <br> Hybri <br> d | QKI:MT- <br> RNR2 | Noisy spanning reads with insertion and reads do not span a lot of bases |
| JAFFA <br> Hybri <br> d | QKI:CREBZF | Low frequency (0.00001\%) |
| JAFFA <br> Hybri <br> d | PTPRZ1:VAPA | No spanning reads in alignment to fusion construct |
| JAFFA <br> Hybri <br> d | PTPRZ1:MTRNR2 | No spanning reads in alignment to fusion construct |
| JAFFA | NTRK2:MTRNR2 | Noisy spanning reads and reads do not span a lot of bases |

```
Hybri
d
JAFFA MYO7A- Homology (Part of read in PCDGH maps multiply to other regions in
- PCDHGA1 transcriptome)
Hybri
d
JAFFA XPNPEP3- Homology (Part of read in PCDGH maps multiply to other regions in
- PCDHGA1 transcriptome)
Hybri
d
JAFFA RTN4-NTRK3 Low frequency (0.002%)
-
Hybri
d
JAFFA ATG7-VGLL4 Low frequency (0.02%)
-
Hybri
d
JAFFA ATG7-TSEN2 Homology (the TSEN2 part aligns multiply to other regions of transcriptome)
Hybri
d
JAFFA ATG7-CLASP2 Homology (the CLASP2 part aligns multiply to other regions of transcriptome)
-
Hybri
d
JAFFA LINC00886- Low frequency and LINCO0886 is non protein coding RNA (0.00003%)
- PCDHGA1
Hybri
d
JAFFA SRGAP3- Homology (The read from SRGAP3 also maps to OXTR)
- OXTR
```

```
Hybri
d
JAFFA PDGFRA-MT- No spanning reads in alignment to fusion construct
- RNR2
Hybri
d
JAFFA PCDHA3- Homology (PCDH family)
- PCDHGA1
Hybri
d
JAFFA RNF130- Homology (RNF part is homologous to other regions in transcriptome)
- DDX46
Hybri
d
```

| JAFFA <br> Hybri <br> d | $\begin{aligned} & \text { CTD- } \\ & \text { 2007H13.3- } \\ & \text { PCDHGA1 } \end{aligned}$ | Pseudogene (CTD-2007H13.3 is a processed pseudogene) |
| :---: | :---: | :---: |
| JAFFA <br> Hybri <br> d | PACRG-QKI | Low frequency (0.00003\%) |
| JAFFA <br> Hybri <br> d | QKI-MT- <br> RNR1 | Noisy spanning reads with insertion and reads do not span a lot of bases |
| JAFFA <br> Hybri <br> d | PTPRZ1-RNY4 | Homology (The part that aligns to RNY1 is highly homologous to various regions across transcriptome) |
| JAFFA <br> Hybri <br> d | PTPRZ1-RNY3 | Homology (The part that aligns to RNY3 is highly homologous to various regions across transcriptome) |
| JAFFA <br> Hybri <br> d | PTPRZ1-RNY1 | Homology (The part that aligns to RNY4 is highly homologous to various regions across transcriptome) |
| JAFFA <br> Hybri <br> d | PTPRZ1- <br> KIAA2026 | Low complexity (KIAA2026 is highly repetitive) |
| JAFFA <br> Hybri <br> d | VOPP1-EGFR | Homology (VOPP1 part is 100\% identical to other regions of transcriptome) |
| JAFFA <br> Hybri <br> d | FGFR1- | Low complexity (The part of AHSA2 is composed of repeats) |
| JAFFA <br> Hybri <br> d | LINC00476PCDHGA1 | Low freqeuncy (0.002\%) and LINC00476 is non protein coding RNA |
| JAFFA <br> Hybri <br> d | MT-RNR2NTRK2 | Noisy alignments with insertion |
| JAFFA <br> Hybri <br> d | LINC01420FAAH2 | No spanning reads in alignment to fusion construct |

```
JAFFA JPX-KTN1 Low complexity in KTN1 region (KTN1 gene has T and A repeats)
Hybri
d
JAFFA JPX-XIST Low complexity (XIST part has a lot of T repeats)
-
Hybri
d
JAFFA UBE2J2- Homology (EEF1D part is 100% identical to other regions in transcriptome)
- EEF1D
Hybri
d
JAFFA ZNF813- Noisy alignments
- NTRK1
Hybri
d
JAFFA RSRC1-EGFR Low complexity (The RSRC1 has a lot of AG repeats)
Hybri
d
JAFFA QKI-PACRG Low complexity (PACRG part is highly repetitive)
-
Hybri
d
JAFFA RPS18- Low complexity (RPS18 part is highly repetitive)
- PCDHGA1
Hybri
d
JAFFA EGFR-PARD3 Low frequency (0.00006%)
Hybri
d
JAFFA EGFR-MT- No spanning reads in alignment to fusion construct
- RNR2
Hybri
d
JAFFA GNAI1-ISPD Low complexity and repeats in ISPD part
-
Hybri
d
JAFFA GNAI1-PTK2 Low complexity and repeats around breakpoint and GNAI1-PTK2 part
Hybri
d
JAFFA UBE2J2-USP4 No spanning reads in alignment to fusion construct
-
Hybri
d
```

| JAFFA <br> Hybri <br> d | THBS1PCDHGA1 | Low complexity (THBS1 is highly repetitive) |
| :---: | :---: | :---: |
| JAFFA <br> Hybri <br> d | PRKCA- <br> RNA5-8S5 | No spanning reads in alignment to fusion construct |
| JAFFA <br> Hybri <br> d | RAF1-ACTG1 | No spanning reads in alignment to fusion construct |
| JAFFA <br> Hybri <br> d | SMIM4PCDHGA1 | Low frequency (0.005\%) |
| JAFFA <br> Hybri <br> d | PCDHGA1- <br> LILRB4 | No spanning reads in alignment to fusion construct |
| JAFFA <br> Hybri <br> d | MYB-PARG | Noisy alignments |
| JAFFA <br> Hybri <br> d | QKI-MT- <br> RNR2 | Noisy alignments |
| JAFFA <br> Hybri <br> d | QKI-SOX10 | Noisy alignment with insertion |
| JAFFA <br> Hybri <br> d | QKI-RBM4 | Low complexity (Poly A repeats) |
| JAFFA <br> Hybri <br> d | QKI-ZNF595 | Homology (The ZNF595 part is highly identical to other regions in transcriptome) |
| JAFFA <br> Hybri <br> d | QKI-SCAF8 | No spanning reads in alignment to fusion construct |
| JAFFA <br> Hybri <br> d | PTPRZ1- <br> SAMD4A | Homology (The SAMD4A part is identical to other regions in transcriptome) |

```
JAFFA PTPRZ1- Low complexity (T repeats in the PSMB1 region)
- PSMB1
Hybri
d
JAFFA PTPRZ1- Low frequency (0.00025%)
- TCAF1
Hybri
d
JAFFA BRAF-MT- No spanning reads in alignment to fusion construct
- RNR2
Hybri
d
JAFFA FGFR1-MT- No spanning reads in alignment to fusion construct
- RNR2
Hybri
d
JAFFA MT-RNR2- No spanning reads in alignment to fusion construct
- NTRK2
Hybri
d
JAFFA MT-RNR2- Noisy alignments
- QKI
Hybri
d
JAFFA JPX- Homology (AC026150.8 is highly homologous to other regions in transcriptome)
- ACO26150.8
Hybri
d
JAFFA TPM3:MRPS2 Homology (TPM3 and MRPS21 part maps to other regions in transcriptome)
- 1
Hybri
d
JAFFA QKI:MT- No spanning reads in alignment to fusion construct
- RNR2
Hybri
d
JAFFA QKI:LARP4B Homology (The LARP4B part maps to other regions in transcriptome)
-
Hybri
d
JAFFA PTPRZ1:ZNF8 Homology (The ZNF81 part also maps to other regions non specific mappings)
- 1
Hybri
d
JAFFA PTPRZ1:RNY4 Homology (Mapping in PTPRZ1 and RNY4 multiple map to several regions across
-
                                    transcriptome)
Hybri
d
```



```
JAFFA QKI:MT- Homology (The MT-RNR2 maps multiply to several regions)
- RNR2
Hybri
d
JAFFA HLA-C:HLA-A Homology (HLA genes)
Hybri
d
JAFFA BRAF:MT- No spanning reads in alignment to fusion construct
- ND2
Hybri
d
JAFFA FGFR1:RNA5- No spanning reads in alignment to fusion construct
- 8S5
Hybri
d
JAFFA MMP16:MT- No spanning reads in alignment to fusion construct
- CO1
Hybri
d
JAFFA NTRK2:RNY1 No spanning reads in alignment to fusion construct
-
Hybri
d
JAFFA JPX:STAG2 Homology and Low complexity (STAG2 part)
Hybri
d
JAFFA SLC7A11- Homology (SLC7A11 part maps multiply to other regions)
- AS1:QKI
Hybri
d
JAFFA PTPRZ1:Y_RN Homology (The Y_RNA part maps multiply to other regions)
- A
Hybri
d
SEEKF QKI-CASK Homology (QKI and CASK parts map multiply to other regions)
USIO
N
SEEKF QKI:APP Homology (RAB2A part maps multiple to other regions)
USIO
N
SEEKF RAB2A:QKI Homology (Part of APP maps to other regions within transcriptome)
USIO
N
```


### 1.6 Supplementary Table 6: Gene Fusions validated

| Assay Type <br> Neurological cancer | Expected KIAA1549-BRAF | Observed KIAA1549-BRAF E16-E9 |
| :---: | :---: | :---: |
| Neurological cancer | FGFR3-TACC3 | FGFR3-TACC3 E17-E8 |
| Neurological cancer | $\begin{gathered} E G F R- \\ E G F R \text { E1-E8 } \end{gathered}$ | EGFR-EGFR E1-E8 |
| Neurological cancer |  | EGFR-PSPH E24-E8 |
| Neurological cancer |  | EGFR-FKBP9L E7-E4 |
| Neurological cancer |  | EGFR-SEPT14 E24-E10 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E15-E9 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E16-E11 |
| Neurological cancer | SRGAP3-RAF1 | SRGAP3-RAF1 E10-E9 |
| Neurological cancer | EGFR-SEPT14 | EGFR-SEPT14 E24-E10 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E16-E9 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E15-E9 |
| Neurological cancer | EGFR-EGFR E1-E8 | EGFR-EGFR E1-E8 |
| Neurological cancer | KIF21B-NTRK1 | KIF21B-NTRK1 E14-E10 |
| Neurological cancer | YAP1 rearrangement | YAP1-FAM118B E7-E3 |
| Neurological cancer | EGFR-EGFR E1-E8 | EGFR-EGFR E1-E8 |
| Neurological cancer | C11orf95-RELA | C11orf95-RELA E3-E3 |
| Neurological cancer | C11orf95-RELA | C11orf95-RELA E3-E3 |
| Neurological cancer | FGFR1-TACC1 | FGFR1-TACC1 E18-E7 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E16-E9 |


| Expected | bserved |
| :---: | :---: |
| PRR12-FOXO1 | PRR12-FOXO1 (11-2) |
| NAB2-STAT6 | NAB2-STAT6 (4-2) |
| NAB2-STAT6 | NAB2-STAT6 (4-2) |
| NAB2-STAT6 | NAB2-STAT6 (4-2) |
| NAB2-STAT6 | NAB2-STAT6 (6-17) |
| NAB2-STAT6 | NAB2-STAT6 (6-17) |
| NAB2-STAT5 | NAB2-STAT5 (6-16) |
| NAB2-STAT6 | NAB2-STAT6 (6-16) |
| SRSF3-USP6 | SRSF3-USP6 (1-10) |
| CDH11-USP6 | CDH11-USP6 (1-9) |
| EWSR1-CREB1 | EWSR1-CREB1 (7-6) |
| ASPSCR1-TFE3 | ASPSCR1-TFE3 (7-5) |
| EWSR1-ATF1 | EWSR1-ATF1 (7-5) |
| EWSR1-ATF1 | EWSR1-ATF1 (11-3) |
| WWTR1-CAMTA1 | WWTR1-CAMTA1 (3-8) |
| WWTR1-CAMTA1 | WWTR1-CAMTA1 (3-8) |
| ETV6-NTRK3 | ETV6-NTRK3 (5-15) |
| ETV6-NTRK3 | ETV6-NTRK3 (5-15) |

Supplementary Material

| Neurological cancer | PDE4B-NTRK2 | PDE4B-NTRK1 E9-E15 |
| :---: | :---: | :---: |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E15-E11 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E16-E9 |
| Neurological cancer | QKI-RAF1 | QKI-RAF1 E3-E8 |
| Neurological cancer | FGFR3-TACC3 | FGFR3-TACC3 E17-E10 |
| $\begin{gathered} \text { Neurological } \\ \text { cancer } \\ \hline \end{gathered}$ | EGFR-EGFR E1-E8 | EGFR-EGFR E1-E8 |
| Neurological cancer | FGFR1-TACC1 | FGFR1-TACC1 E18-E7 |
| Neurological cancer | FGFR3-TACC3 | FGFR3-TACC3 E17-E11 |
| Neurological cancer | EGFR-EGFR E1-E8 | EGFR-EGFR E1-E8 |
| Neurological cancer | QKI-NTRK2 | QKI-NTRK2 E6-E15 |
| Neurological cancer | KIAA1549-BRAF | KIAA1549-BRAF E16-E9 |
| Neurological cancer | NAB2-STAT6 | NAB2-STAT6 E4-E2 |
| Neurological cancer | NAB2-STAT6 | NAB2-STAT6 E4-E2 |
| Neurological cancer | NAB2-STAT6 | NAB2-STAT6 E4-E2 |
| Neurological cancer | EWSR1-FLI1 E7-E6 | EWSR1-FLII E7-E6 |
| Neurological cancer | EWSR1-FLI1 E7-E6 | EWSR1-FLI1 E7-E6 |
| Neurological cancer | EWSR1-FLI1 | EWSR1-FLII E7-E6 |
| Neurological cancer | $\begin{gathered} \hline \text { SRGAP3-RAF1 } \\ \text { E10-E9 } \end{gathered}$ | SRGAP3-RAF1 E10-E9 |
| Neurological cancer | KIAA1549-BRAF E16-E9 | KIAA1549-BRAF E16-E9 |
| Neurological cancer | MYB-QKI E10-E5 | MYB-QKI E10-E5 |



| Neurological cancer | $\begin{gathered} \text { FAM131B-BRAF } \\ \text { E2-E9 } \end{gathered}$ | FAM131B-BRAF E2-E9 | Sarcoma | EP400-PHF1 | EP400-PHF1 (37-2) EP400- <br> PHF1 (37-2) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Neurological cancer | PVT1-MYC E3-E2 | PVT1-MYC E4-E2 | Sarcoma | JAZF1-SUZ12 | JAZF1-SUZ12 (3-2) |
| Neurological cancer | $\begin{gathered} \text { FGFR1-TACC1 } \\ \text { E18-E7 } \end{gathered}$ | FGFR1-TACC1 E18-E7 | Sarcoma | JAZF1-PHF1 | JAZF1-PHF1 (3-2) |
| Neurological cancer | $\begin{gathered} \text { DDX31-GFIIB } \\ \text { E19-E2 } \end{gathered}$ | DDX31-GFIIB E19-E2 | Sarcoma |  | JAZF - |
| Neurological cancer | $\begin{gathered} \text { SLC44A1-PRKCA } \\ \text { E15-E9 } \end{gathered}$ | SLC44A1-PRKCA E15-E9 | Sarcoma | RANBP2-ALK | RANBP2-ALK (18-20) |
| Neurological cancer | MYB-ESR1 E15-E6 | MYB-ESR1 E14-NA | Sarcoma | TRAF3-ALK | TRAF3-ALK (11-20) |
| Neurological cancer | $\begin{aligned} & \hline \text { PTPRZ1-MET E1- } \\ & \text { E2 } \end{aligned}$ | PTPRZ1-MET E1-E2 | Sarcoma | IGFBP5-ALK | IGFBP5-ALK (1-19) |
| Neurological cancer | TPM3-NTRK1 E7E10 | TPM3-NTRK1 E7-E10 | Sarcoma | MPRIP-ALK | MPRIP-ALK (21-20) |
| Neurological cancer | $\begin{gathered} M Y B-P C D H G A 1 \\ \mathrm{E} 9-\mathrm{E} 2 \end{gathered}$ | MYB-PCDHGA1 E9-E2 | Sarcoma | AHRR-NCOA2 | AHRR-NCOA2 (9-11) |
| Neurological cancer | FGFR1-FGFR1 E9E19 | FGFR1-FGFR1 E9-E19* | Sarcoma | AHRR-NCOA2 | AHRR-NCOA2 (10-13) |
| Sarcoma | MIR143HG-NOTCH2 | MIR143HG-NOTCH2 (1- | Sarcoma | EWSR1-ETV1 | EWSR1-ETV1 (7-10) |
| Sarcoma |  |  | Sarcoma | EWSR1-CREB3L1 | EWSR1-CREB3L1 (8-6) |
| Sarcoma | GLII-ACTB | GLI1-ACTB (6-3) | Sarcoma | FUS-CREB3L1 | FUS-CREB3L1 (int 6-6) |
| Sarcoma | HMGA2-LPP | HMGA2-LPP (3-9) |  |  |  |

### 1.7 Supplementary Table 7: Fusions reported in sarcoma and neurological cancer clinical cases

| EGFR VIII | WWTR1-CAMTA1 | BCR-NTRK2 | EIF1-USP6 |
| :--- | :--- | :--- | :--- |
| KIAA1549-BRAF | PAX3-MAML3 | ARHGEF2-NTRK1 | FUS-ERG |
| FGFR3-TACC3 | FUS-CREB3L2 | MN1-MOB3B | RAB2A-BCS1L |
| PTPRZ1-MET | ACTB-GLI1 | MDM4-GLI1 | PRRC2B-ALK |
| C11orf95-RELA | EP400-PHF1 | EML4-NTRK3 | CIC-FOXO4 |
| FGFR1-TACC1 | ZC3H7B-BCOR | CAND1-EGFR | CALD1-USP6 |
| EGFR-SEPT14 | PHF1-TFE3 | TRIM24-MET | ATIC-ALK |
| CAPZA2-MET | MYH9-USP6 | PTTG1IP-BRAF | GLI1-ACTB |
| NAB2-STAT6 | EML4-ALK | FGFR3-FAM184B | HMGA2-RAB3IP |
| GTF2I-BRAF | EWSR1-CREB3L1 | FGFR3-PLEC | EWSR1-BEND2 |
| ATG7-RAF1 | EWSR1-NR4A3 | TPR-NTRK1 | CIC-DUX4L4 |
| GKAP1-NTRK2 | EWSR1-PBX3 | MBNL1-RAF1 | CNBP-PDCD11 |

Supplementary Material

| SLC44A1-PRKCA | PAX7-FOXO1 | EVI5-BRAF | MYBL1-NFIB |
| :--- | :--- | :--- | :--- |
| AFAP1-NTRK2 | TAF15-NR4A3 | PID1-BRAF | TFG-NTRK3 |
| GNAI1-BRAF | RNF213-ALK | FGFR1-FGFR1 | TFG-ZBTB10 |
| ZSCAN21-MET | MXD4-NUTM1 | EWSR1-FLI1 | YAP1-C15orf55 |
| EWSR1-CREB1 | MIR143HG-NOTCH2 | EWSR1-ERG | NCOA2-SPIDR |
| TRIO-NTRK2 | JAZF1-SUZ12 | SS18-SSX1 | SRF-NCOA2 |
| LACE1-QKI | ETV6-NTRK3 | EWSR1-WT1 | EWSR1-GFI1B |
| EWSR1-ETV1 | BCOR-ZC3H7B | PAX3-FOXO1 | EWSR1-CREB3L2 |
| MN1-BEND2 | AHRR-NCOA2 | EWSR1-ATF1 | HMGA2-LEMD3 |
| YAP1-MAML2 | YWHAE-NUTM2B | COL1A1-PDGFB | EWSR1-POU5F1P3 |
| ST7-MET | EWSR1-NFATC2 | FUS-DDIT3 | RBM10-TFE3 |
| BCAN-NTRK1 | LMNA1-TFCP2 | BCOR-CCNB3 | FBXO32-PLAG1 |
| PRKAR2B-BRAF |  |  |  |

## 2 Supplementary methods

### 2.1 Specimen requirements:

This assay requires at least $10 \%$ tumor nuclei. Preferred amount of tumor area with sufficient percent tumor nuclei: tissue $144 \mathrm{~mm}(2)$. Minimum amount of tumor area: tissue $36 \mathrm{~mm}(2)$. These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.Tissue fixation: $10 \%$ neutral buffered formalin, not decalcified

### 2.2 Preferred Specimen Type:

Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue. Container/Tube: Tissue block. Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block.

### 2.3 Acceptable Specimen Type:

Specimen Type: FFPE Tissue. Slides: 1 Stained and 10 unstained. Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 10 unstained, nonbaked slides with 5-micron thick sections of the tumor tissue. Specimen Type: Cytology slide (direct smears or ThinPrep). Slide: 1 to 3 slides. Collection Instructions: Submit 1 to 3 slides stained and coverslipped with a preferred total of 5000 nucleated cells or a minimum of at least 3000 nucleated cells. Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.

### 2.4 Deduping methods:

The UMI consensus is built as follows:

Say, we denote the real (but unknown) base as $R \in S$ where $S=[A, T, G, C]$ is our alphabet. Denote the observed bases $O_{n} \in S, n=1, \ldots, N$ and their corresponding quality $\operatorname{scores} Q_{n} \in$ $R_{+} n=1, \ldots, N$. The quality scores can be converted into their corresponding error probabilities $P_{n}^{e r r}=10^{\frac{-Q_{n}}{10}}, n=1, \ldots N$. Then we use Bayes' theorem to iteratively update our knowledge about the real base $R$. Specifically, we assign a prior distribution $P[R=A]=$ $P[R=T]=\frac{1-P^{G C}}{2}$ and $P[R=G]=P[R=C]=P^{G C} / 2$, where the GC percent of the region $P^{G C}$ can be computed genome-wide. Then for each observation we apply Bayes' theorem to update our knowledge, starting with the first observation:

$$
P\left[R=r \mid O_{1}=o_{1}\right]=\frac{P\left[O_{1}=o_{1} \mid R=r\right] P[R=r]}{\sum_{x \in S} P\left[O_{1}=o_{1} \mid R=x\right] P[R=x]}, r \in S, o 1 \in S
$$

Where the likelihood probabilities can be computed from $P_{1}^{e r r}$ as

$$
P\left[O_{1}=o_{1} \mid R=r\right]=\left[1-P_{1}^{e r r}\right] \delta_{o_{1}, r}+\frac{P_{1}^{e r r}\left[1-\delta_{o_{1}, r}\right]}{3}, r \in S, o_{1} \in S
$$

Where $\delta_{o_{1}, r}$ is the Kronicker delta that equals one when its subscripts are equal and zero otherwise. Then at stage $n$ where $P\left[r \mid o_{1}, \ldots, o_{n}\right]$ is computed, the next observation $o_{n+1}$ for each $r \in S$ using assumption that observations of sequences are independent of each other.

$$
\begin{gathered}
P\left[r \mid o_{1} \ldots, o_{n+1}\right]=\frac{\left(P\left[o_{n+1} \mid r, o_{1} \ldots, o_{n}\right] P\left[r \mid o_{1} \ldots, o_{n}\right]\right)}{\sum_{x \in S}\left(P\left[o_{n+1} \mid x, o_{1} \ldots, o_{n}\right] P\left[x \mid o_{1} \ldots, o_{n}\right]\right)} \\
=\frac{P\left[o_{n+1} \mid r\right] P\left[r \mid o_{1} \ldots, o_{n}\right]}{\sum_{x \in S}\left(P\left[o_{n+1} \mid x\right] P\left[x \mid o_{1} \ldots, o_{n}\right]\right)}
\end{gathered}
$$

Finally, once we have iterated through all our observations, we make a consensus estimate for the real base $\hat{R}$ using the maximum a posteriori (MAP) estimate: $\hat{R}=\operatorname{argmax}_{R \in S} P\left[r \mid o_{1} \ldots o_{n}\right]$ and the corresponding updated error probability estimate is given by: $\widehat{P^{e r r}}=1-P\left[\hat{R} \mid o_{1} \ldots o_{n}\right]$ which provides updated score estimate: $\widehat{Q_{n}}=-10 \log _{10}\left(\widehat{P^{e r r}}\right)$.

Mononucleotide repeat ratio calculation:

Say there is a sequence where there are 3 mononucleotides that are repeated

$$
\begin{gathered}
\left(X_{i}, X_{i+1}, X_{i+2}, X_{i+3}, X_{i+4}, X_{i+5} \ldots X_{n}\right) \text { where } X_{i}, \cdots, X_{n} \in[A, T, G, C] \text { and } X_{i+2}=X_{i+3}= \\
X_{i+4} \text { are the repeated mononucleotides }
\end{gathered}
$$

Each nucleotide is assigned a score, $S=1$ and for the above sequence the mononucleotide repeat ratio is defined by the formula:

$$
M R R=\frac{\left\{S_{i}^{2}+S_{i+1}^{2}+\left(S_{i+2}+S_{i+3}+S_{i+4}\right)^{2}+S_{i+5}^{2}+\cdots+S_{n}^{2}\right\}}{n}
$$

For a region with no mononucleotide repeats, the MRR value is equal to 1 . For a region with high repeats the value increases based on the length of mononucleotide repeat signatures. For every assembled contig that mapped to a region in the genome, the region is assessed for mononucleotide repeat ratio and the regions with ratio greater than an empirically chosen threshold of 10 are not considered as potential fusion partners.

### 2.5 UMI and Adapter sequence trimming

UMIs are $1^{\text {st }} 12$ bases of read 2 in the chemistry.

```
>R1_adapter
AGGACTCCAAT
>R2_adaper
CAAAACGCAATACTGTACATT
>R2_adapter_rev
AATGTACAGTATTGCGTTTTG
>polyA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
>polyT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
```

The adapter and UMIs were trimmed using FASTP.

## 3 Raw data availability

All benchmarking raw data has been uploaded to NCBI's SRA website.

| NCBI SRA ID | URL | SampleID in study |
| ---: | :--- | :--- |
| 21386667 | https//www.ncbi.nlm.nih.gov/sra/21386667 | pos_S1_KIAA1549fusionBRAF |
| 21386668 | https//www.ncbi.nlm.nih.gov/sra/21386668 | pos_S11_QKIfusionRAF1 |
| 21386669 | https//www.ncbi.nlm.nih.gov/sra/21386669 | pos_S10_PDE4BfusionNTRK2 |
| 21386670 | https//www.ncbi.nlm.nih.gov/sra/21386670 | pos_S12_NAB2fusionSTAT6 |

Supplementary Material

| 21386671 | https//www.ncbi.nlm.nih.gov/sra/21386671 | pos_S7_MN1fusionMOB3B |
| :---: | :---: | :---: |
| 21386672 | https//www.ncbi.nlm.nih.gov/sra/21386672 | pos_S6_FGFR3fusionTACC3 |
| 21386673 | https//www.ncbi.nlm.nih.gov/sra/21386673 | pos_S4_EWSR1fusionFLI1 |
| 21386674 | https//www.ncbi.nlm.nih.gov/sra/21386674 | pos_S2_EGFRfusionSEPT14 |
| 21386675 | https//www.ncbi.nlm.nih.gov/sra/21386675 | pos_S3_EGFR1fusionEGFR8 |
| 21386676 | https//www.ncbi.nlm.nih.gov/sra/21386676 | pos_S9_C11ORF95fusionRELA |
| 21386677 | https//www.ncbi.nlm.nih.gov/sra/21386677 | pos_S5_BRAFfusionFAM131B |
| 21386678 | https//www.ncbi.nlm.nih.gov/sra/21386678 | pos_S13_POSITIVEfusionCONTROL |
| 21386679 | https//www.ncbi.nlm.nih.gov/sra/21386679 | pos_S8_SRGAP3fusionRAF1 |
| 21386680 | https//www.ncbi.nlm.nih.gov/sra/21386680 | pos_S14_Insilico |
| 21386681 | https//www.ncbi.nlm.nih.gov/sra/21386681 | neg_S1_sample1 |
| 21386682 | https//www.ncbi.nlm.nih.gov/sra/21386682 | neg_S2_sample2 |
| 21386683 | https//www.ncbi.nlm.nih.gov/sra/21386683 | neg_S3_sample3 |
| 21386684 | https//www.ncbi.nlm.nih.gov/sra/21386684 | neg_S4_sample4 |
| 21386685 | https//www.ncbi.nlm.nih.gov/sra/21386685 | neg_S5_sample5 |
| 21386686 | https//www.ncbi.nlm.nih.gov/sra/21386686 | neg_S6_sample6 |
| 21386687 | https//www.ncbi.nlm.nih.gov/sra/21386687 | neg_S7_sample7 |
| 21386688 | https//www.ncbi.nlm.nih.gov/sra/21386688 | neg_S8_sample8 |
| 21386689 | https//www.ncbi.nlm.nih.gov/sra/21386689 | neg_S9_sample9 |

## 4 Docker Accessiblity and instructions to run pipeline in docker

### 4.1 Instructions to use it in linux machine/mac/windows:

- Create a new account if you don't have one here - https://hub.docker.com/signup
- Download and install docker as per operating system use
- Make sure that in the docker config the memory is set to at least 6GB
- Open terminal, and pull from seekfusion docker-
- docker pull jagadhesh89/seekfusion
- Ensure that you are running jagadhesh89/seekfusion
- docker run -i -t jagadhesh89/seekfusion
- Run the pipeline with files in the docker image (this command also available on dockerhub page)
- pipeline/v2.00.00/src/NGS_UMIFUSION/main/shell/runFusion.sh -i /pipeline/test_data/ -m local
- The outputs are available in /pipeline/test_data under umifusion directory.
- The vcf file output is under under /pipeline/test_data/umifusion/reports/*.vcf
- The sample data contains the EWSR1-NR4A3 fusion and NTRK2-VCL fusion.
- The sample output directory needs to be backed up, renamed or removed while testing.


### 4.2 Screenshots



ORDERED SERVICE DATA

| TEST_DEF_HOME: | /testDefinition |
| :--- | :--- |
| RECIPE: | TEST |
| MASTER_PANEL: |  |
| PROJECT_NAME: | TESTRUN |
| OS_CONFIG: | /pipeline/test_data/umifusion/configs/os.cfg |
| OS_PIPELINE_DIR: | /pipeline/test_data/ordered_service/pipelines/umifusion |
| WDL DATA |  |
|  |  |
| JSON_INPUT: | /pipeline/test_data/umifusion/configs/inputs.json |
| JSON_CONFIG: | /pipeline/test_data/umifusion/configs/configs.json |
| CROMWELL_FOLDER: | /temp/cromwell |
| CROMWELL_LOGS: | /logs/umifusion |
| SGE_CONFIG: | /pipeline/v2.00.00/configs/local.conf |
| OUTPUT_JSON: | /pipeline/test_data/umifusion/configs/outputs.json |
|  |  |
| RESULTS |  |
| OUTPUT_DIR: |  |
| CONFIG_DIR: | /pipeline/test_data/umifusion |
| DEVICE_NAME: | /pipeline/test_data/umifusion/configs |

[2021-09-16T18:25:58+0000] [INFO] [runFusion.sh]
[2021-09-16T18:25:58+0000] [INFO] [runFusion.sh]
[2021-09-16T18:25:58+0000] [INFO] [runFusion.sh] /usr/bin/java -Dbackend.providers.SGE.config.root=/temp/cromwell -Dworkflow-options.workflow-
log-dir=/logs/umifusion -Dconfig.file=/pipeline/v2.00.00/configs/local.conf -Xmx8G -Xms4G -Xss4M -jar /biotools/cromwell/cromwell-49.jar run /pipeline/v2.00.00/src/NGS_UMIFUSION/main/wdl/fusion.wdl -p/pipeline/v2.00.00/src/NGS_UMIFUSION/src.zip -i /pipeline/test_data/umifusion/con figs/inputs.json -o/pipeline/test_data/umifusion/configs/configs.json -m/pipeline/test_data/umifusion/configs/outputs.json | tee -a /pipeline/test_ data/umifusion/logs/main.log

